RAPAM.12 Form # 20910 R: 12.13

Fax: 1-888-879-6938

State of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form Psoriasis- Biologicals

www.mainecarepdl.org

Phone: 1-888-445-0497

Member ID #: _ _ _ Patient Name:			DOB:	
Patient Address:				
Provider DEA: _ Provider NPI: _				
Provider Name:			Phone:	
Provider Address:				
Pharmacy Name:				
(Pharmacy use only): NPI: NABP: NDC: NDC:				
Enbrel and Humira are preferred if prior trial of at least one of the following is in member's drug profile: methotrexate, cyclosporine, methoxsalen or acitretin.				
Drug Name Strength Dosa	ge Instructions		Days Supply (34 retail / 84 mail order)	Circle Refills
□ Enbrel (8)	BIW		<u>28</u>	1 2 3 4 5
☐ Amevive®®®				1 2 3 4 5
☐ Stelara ⁽⁸⁾				1 2 3 4 5
□ Other				1 2 3 4 5
Medical Necessity Documentation 1) Diagnosis:				
1.) <u>Diagnosis</u> : 2.) <u>Requirements</u> : (Must meet ALL requirements)				
☐ Must have topical or systemic psoriasis treatment in history within past 6 months				
☐ Failed trial of Enbrel (for Amevive)				
☐ Several topicals (list):				
Oral agent (list):				
☐ Phototherapy UVA				
3.) Enbrel (high dose)				
☐ Met all requirements listed above				
☐ Failure on Enbrel 25mg BIW or 50mg QW dosing☐ High dose Enbrel 50mg BIW will be allowed 12 weeks approval only after failure of all traditional				
psoriasis therapies.				
Pursuant to the MaineCare Benefits Manual, Chapter I, Section 1.16, The Department regards adequate clinical records as essential for the delivery of quality care, such comprehensive records are key documents for post payment review. Your authorization certifies that the above request is medically necessary, meets the MaineCare criteria for prior authorization, does not exceed the medical needs of the member and is supported in your medical records. Provider Signature: Date of Submission:				